Get the Stockscreener App
12.44
2.74%
-0.35
After Hours:
12.44
Xencor Inc stock is traded at $12.44, with a volume of 664.32K.
It is down -2.74% in the last 24 hours and up +0.16% over the past month.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
See More
Previous Close:
$12.79
Open:
$12.84
24h Volume:
664.32K
Relative Volume:
0.82
Market Cap:
$922.32M
Revenue:
$125.58M
Net Income/Loss:
$-92.14M
P/E Ratio:
-10.01
EPS:
-1.2424
Net Cash Flow:
$-138.27M
1W Performance:
-3.19%
1M Performance:
+0.16%
6M Performance:
-13.55%
1Y Performance:
+41.85%
1-Day Range:
$12.40
$13.00
1-Week Range:
$12.00
$13.49
52-Week Range:
$6.92
$18.69
Xencor Inc Stock (XNCR) Company Profile
Name
Xencor Inc
Sector
Industry
Phone
626-305-5900
Address
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
12.44 | 948.27M | 125.58M | -92.14M | -138.27M | -1.2424 |
VRTX
Vertex Pharmaceuticals Inc
|
448.29 | 110.45B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
723.41 | 74.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
812.81 | 50.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
292.03 | 38.03B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
315.07 | 32.24B | 5.36B | 287.73M | 924.18M | 2.5229 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-26 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-24-25 | Initiated | Truist | Buy |
| Oct-29-25 | Upgrade | Barclays | Underweight → Overweight |
| Sep-17-25 | Resumed | Barclays | Underweight |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-21-25 | Initiated | William Blair | Outperform |
| Dec-12-24 | Initiated | Wells Fargo | Overweight |
| Dec-02-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-16-24 | Reiterated | BTIG Research | Buy |
| Feb-28-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-23 | Initiated | BofA Securities | Buy |
| Dec-06-22 | Initiated | Cowen | Outperform |
| Oct-13-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-21-22 | Initiated | SMBC Nikko | Outperform |
| Dec-15-21 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Feb-24-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Feb-25-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-30-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| Aug-07-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-07-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-13-19 | Initiated | Mizuho | Buy |
| Apr-12-19 | Initiated | Guggenheim | Buy |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Mar-15-19 | Initiated | Raymond James | Outperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Mar-02-17 | Initiated | Instinet | Neutral |
| Mar-02-17 | Reiterated | Wedbush | Outperform |
| Oct-04-16 | Initiated | Piper Jaffray | Overweight |
| Dec-22-15 | Initiated | Canaccord Genuity | Buy |
| Aug-05-15 | Reiterated | MLV & Co | Buy |
| Feb-12-15 | Reiterated | Oppenheimer | Outperform |
| Jan-28-15 | Reiterated | MLV & Co | Buy |
| Jul-11-14 | Initiated | Oppenheimer | Outperform |
View All
Xencor Inc Stock (XNCR) Latest News
Xencor stock (US98401F1057): Biotech innovator in antibody therapies - AD HOC NEWS
Xencor Is Maintained at Neutral by JP Morgan - Moomoo
TD Cowen Maintains Xencor(XNCR.US) With Buy Rating - Moomoo
Xencor (NASDAQ:XNCR) Price Target Raised to $14.00 at JPMorgan Chase & Co. - MarketBeat
These Analysts Just Made A Huge Downgrade To Their Xencor, Inc. (NASDAQ:XNCR) EPS Forecasts - simplywall.st
Xencor (NASDAQ:XNCR) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
Xencor (XNCR) Receives a Buy from Wells Fargo - The Globe and Mail
These Analysts Think Xencor, Inc.'s (NASDAQ:XNCR) Sales Are Under Threat - Yahoo Finance
Xencor (NASDAQ:XNCR) Downgraded by Zacks Research to "Strong Sell" - MarketBeat
Xencor, Inc. (XNCR) Stock Analysis: Exploring A 132% Potential Upside In Biotech - DirectorsTalk Interviews
Xencor (XNCR) Q1 Loss Surges To US$128.9 Million Challenging Bullish Growth Narratives - Sahm
MSN Money - MSN
Number of shareholders of Xencor, Inc. – MUN:XE9 - TradingView
Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Xencor (NASDAQ:XNCR) Releases Earnings Results, Misses Estimates By $1.06 EPS - MarketBeat
Earnings Flash (XNCR) Xencor, Inc. Reports Q1 Revenue $4.5M - marketscreener.com
Xencor: Q1 Earnings Snapshot - kens5.com
Xencor (NASDAQ: XNCR) posts deeper Q1 2026 loss amid royalty dispute and Zenas write-down - Stock Titan
Xencor, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Xencor (NASDAQ: XNCR) Q1 loss widens as revenue and royalties fall - Stock Titan
Xencor Reports First Quarter 2026 Financial Results - Business Wire
Xencor trying to close in on key technical benchmark - MSN
Xencor Highlights XmAb942 Phase 1 Data, Previews TL1A/IL-23 Bispecific XmAb412 at DDW 2026 - MarketBeat
Xencor (XNCR) Earnings Date and Reports 2026 - MarketBeat
Buy Rating on Xencor as TL1A Franchise Data and Upcoming Phase IIb Catalyst Support Upside Potential - TipRanks
Xencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412Slideshow - Seeking Alpha
Behavioral Patterns of XNCR and Institutional Flows - Stock Traders Daily
Xencor Highlights TL1A Autoimmune Portfolio and IBD Strategy - TipRanks
Xencor presents Phase 1 XmAb942 final results; XmAb412 FIH study on track for 3Q26 - TradingView
Xencor (XNCR) expands TL1A franchise with XmAb942 data and XmAb412 moving to clinic - Stock Titan
Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW - Business Wire
Xencor (XNCR) Projected to Post Earnings on Wednesday - MarketBeat
Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Xencor (NASDAQ:XNCR) Stock Price Down 8%Should You Sell? - MarketBeat
Xencor Adopts Executive Severance Policy to Support Retention - The Globe and Mail
Xencor Gears Up For DDW 2026 Readouts, 2H26 Pipeline Catalysts - RTTNews
Xencor (NASDAQ:XNCR) Stock Passes Above 50 Day Moving AverageTime to Sell? - MarketBeat
Xencor (NASDAQ: XNCR) seeks approval for 4M new equity plan shares and auditor - Stock Titan
[ARS] Xencor Inc SEC Filing - Stock Titan
Executive severance plan at Xencor (NASDAQ: XNCR) adds change-in-control terms - Stock Titan
(XNCR) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
XNCR (Xencor Inc.) reports far narrower Q4 2025 loss than expected alongside 13.7% year over year revenue growth.Financial Data - UBND thành phố Hải Phòng
Is Xencor (XNCR) stock trending sideways or preparing to move (-0.31%) 2026-04-20Stock Idea Sharing Hub - Cổng thông tin điện tử tỉnh Lào Cai
Xencor (NASDAQ:XNCR) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Xencor (NASDAQ:XNCR) Shares Pass Above Fifty Day Moving AverageTime to Sell? - MarketBeat
Ideas Watch: Is Xencor Inc impacted by rising rates2026 Earnings Surprises & Weekly Top Stock Performers List - baoquankhu1.vn
Xencor CFO Cornelissen sells $42990 in stock - Investing.com
Xencor CFO Cornelissen sells $42990 in stock By Investing.com - Investing.com India
Xencor (XNCR) CFO sells 3,499 shares to cover tax on vested RSUs - Stock Titan
Short Covering: What is the target price for Xencor Inc stockPortfolio Value Report & Short-Term High Return Ideas - baoquankhu1.vn
How (XNCR) Movements Inform Risk Allocation Models - Stock Traders Daily
Xencor Inc Stock (XNCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):